Skip to main content
. 2021 Jul 29;61(5):1810–1818. doi: 10.1093/rheumatology/keab570

Fig. 1.


Fig. 1

Relative risks for cancer overall in RA, by bDMARD treatment status

(A) In each of the RA treatment cohorts vs. the general population. (B) In bDMARD-treated RA vs. bDMARD-naïve RA.

TNFi: TNF inhibitor; b/tsDMARD: biologic and targeted synthetic DMARD.